Literature DB >> 10456345

Mucosal morbidity in patients with epidermolysis bullosa acquisita.

M C Luke1, T N Darling, R Hsu, R M Summers, J A Smith, B I Solomon, G R Thomas, K B Yancey.   

Abstract

BACKGROUND: Epidermolysis bullosa acquisita is an acquired inflammatory and/or dermolytic subepidermal blistering disease characterized by IgG autoantibodies to type VII collagen. Four patients with documented epidermolysis bullosa acquisita were evaluated by a multidisciplinary team of care providers (4 dermatologists, an ophthalmologist, a radiologist, a voice and speech specialist, and an otolaryngologist) for 1 to 5 years to characterize mucosal involvement and its complications and response to treatment. Patients were evaluated clinically and by slitlamp examinations, endoscopies, computed tomographic scans, and videofluorographic swallowing studies. Spiral computed tomographic scans for virtual endoscopy were used for the nontraumatic evaluation of airways in 2 patients with respiratory tract compromise. OBSERVATIONS: Involvement of 5 or more mucosal sites--mouth, nose, conjunctiva, pharynx, and larynx--was documented in all patients. Complications included ankyloglossia, periodontal disease, scarring and crusting of nasal mucosa, symblepharon formation, obstruction of nasolacrimal ducts, deformation of the epiglottis, impaired phonation, dysphagia, esophageal strictures, and supraglottic stenosis requiring emergency tracheostomy.
CONCLUSIONS: Epidermolysis bullosa acquisita may extensively (or predominantly) affect mucosal epithelia in a manner resembling cicatricial pemphigoid. Mucosal disease in these patients is often subclinical, can lead to serious complications, and is best managed using a multidisciplinary approach.

Entities:  

Mesh:

Year:  1999        PMID: 10456345     DOI: 10.1001/archderm.135.8.954

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  18 in total

1.  [Mucosal epidermolysis bullosa acquisita complicated by laryngeal stenosis].

Authors:  S Ritzmann; W Angerstein; N J Neumann; M Megahed
Journal:  Hautarzt       Date:  2004-10       Impact factor: 0.751

Review 2.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Dapsone in the management of autoimmune bullous diseases.

Authors:  Evan W Piette; Victoria P Werth
Journal:  Dermatol Clin       Date:  2011-10       Impact factor: 3.478

4.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 5.  Diagnosis and management of cricopharyngeal achalasia and other upper esophageal sphincter opening disorders.

Authors:  I J Cook
Journal:  Curr Gastroenterol Rep       Date:  2000-06

6.  Anti-BP180-type mucous membrane pemphigoid immunoglobulin G shows heterogeneity of internalization of BP180/collagen XVII into keratinocyte cytoplasm.

Authors:  Akiko Imanishi; Hisayoshi Imanishi; Sho Hiroyasu; Toshiyuki Ozawa; Hiroshi Koga; Norito Ishii; Yasuo Kitajima; Takashi Hashimoto; Daisuke Tsuruta
Journal:  Med Mol Morphol       Date:  2015-12-10       Impact factor: 2.309

Review 7.  Mucous membrane pemphigoid.

Authors:  Hong-Hui Xu; Victoria P Werth; Ernesta Parisi; Thomas P Sollecito
Journal:  Dent Clin North Am       Date:  2013-08-15

Review 8.  Dapsone in the management of autoimmune bullous diseases.

Authors:  Evan W Piette; Victoria P Werth
Journal:  Immunol Allergy Clin North Am       Date:  2012-04-18       Impact factor: 3.479

9.  Epidermolysis bullosa acquisita with moderately severe Dysphagia due to esophageal strictures.

Authors:  Jenny Tu; Prasad W Kumarasinghe
Journal:  Indian J Dermatol       Date:  2011-03       Impact factor: 1.494

Review 10.  [Mucous membrane pemphigoid with ocular involvement. Part I: Clinical manifestations, pathogenesis and diagnosis].

Authors:  E Schmidt; T Meyer-Ter-Vehn; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-03       Impact factor: 1.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.